Medication info
Glicita Tablet 25mg (Sitagliptin Hydrochloride Monohydrate)

Glicita Tablet 25mg (Sitagliptin Hydrochloride Monohydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›28.35mg / 1 tablet
Manufacturer / importer
Donggu Bio Pharmaceutical Co., Ltd.
Appearance
Pink, round double-convex film-coated tablets
Packaging
28 tablets/box [14 tablets/PTPX2]
Approval status
Active

MFDS item code 202102396 · Approved 2021.03.17 · Insurance code 657308550

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
This medicine is administered at a dose of 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken without regard to meals. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (eGFR ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (eGFR ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (eGFR ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (eGFR < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.

Ingredients

Manufacturer
Donggu Bio Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Type 2 diabetes
  • abnormal blood sugar control
View approved original text

This medication is used as an adjunct to diet and exercise to improve blood sugar control in patients with type 2 diabetes. It can be administered alone as an initial treatment, and if a patient has no prior treatment experience and struggles with blood sugar control, it can be used in combination with metformin. Additionally, this medication can be used in combination when blood sugar is not adequately controlled with any one of sulfonylureas, metformin, thiazolidinediones, or insulin. It can also be used in situations where multiple medications need to be combined but blood sugar control remains difficult. Therefore, this medication helps improve blood sugar management at various stages of treatment.

How to take

Adult dose

This medicine is administered at a dose of 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken without regard to meals. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (eGFR ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (eGFR ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (eGFR ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (eGFR < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.

Precautions

This medication can cause allergic reactions; if symptoms such as skin rash or difficulty breathing occur, discontinue use immediately and consult a physician. If severe abdominal pain, a symptom of pancreatitis, occurs while taking this medication, notify healthcare personnel immediately, and discontinue medication if necessary. Patients with type 1 diabetes or diabetic ketoacidosis should not use this medication. Patients with impaired renal function need dosage adjustment of this medication, so regular kidney function tests should be performed, and it should be taken according to physician’s instructions. There is a risk of hypoglycemia when taking this medication, especially when used in combination with insulin or sulfonylureas; blood sugar levels should be monitored frequently, and symptoms should be carefully observed. If severe joint pain or blisters on the skin occur, notify a physician immediately and discontinue medication. Pregnant or breastfeeding women are advised to avoid using this medication, and safety and effectiveness in children have not been established. Elderly patients may require dosage adjustments and regular kidney function tests due to potentially reduced renal function. In cases of overdose, seek medical attention immediately because this medication can be partially removed by dialysis. This medication has fewer drug interactions; however, when used in combination with digoxin, blood concentration levels should be monitored. If any abnormal symptoms occur while taking this medication, consult healthcare personnel immediately.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • hypoglycemia
  • nasopharyngitis
  • upper respiratory infection
  • headache
  • diarrhea
  • abdominal pain
Show 28 more
  • nausea
  • peripheral edema
  • constipation
  • vomiting
  • severe and debilitating arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • pneumonia
  • diabetes complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • dyspepsia
  • dizziness
  • increased serum triglycerides
  • gastritis
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air and moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius to ensure the prolonged effectiveness of the drug.

Appearance and packaging

Appearance

Pink, round double-convex film-coated tablets

Package unit

28 tablets/box [14 tablets/PTPX2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.